Adipokine profile as a novel screening method for cardiometabolic disease: Help or hindrance?

Abstract

Get full access to this article

View all access options for this article.

References

Maury

Brichard

. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1–16.

Menzaghi

Marucci

Antonucci

et al.

Suggestive evidence of a multi-cytokine resistin pathway in humans and its role on cardiovascular events in high-risk individuals. Sci Rep 2017; 7: 44337–44337.

Ouchi

Walsh

. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24–30.

Kanda

Tateya

Tamori

et al.

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494–1505.

Haugen

Drevon

. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007; 148: 5478–5486.

Kobashi

Urakaze

Kishida

et al.

Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005; 97: 1245–1252.

Kim

Yadav

Ahn

et al.

A prospective study of serum adiponectin and regression of metabolic syndrome: The ARIRANG study. Biochem Biophys Res Commun 2015; 466: 201–205.

Tao

Gao

Jiao

et al.

Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408–1416.

Shimizu

Yoshida

Minamino

. Pathological role of adipose tissue dysfunction in cardio-metabolic disorders. Int Heart J 2015; 56: 255–259.

10.

Khan

Ogorodnikova

et al.

The adipokine profile of metabolically benign obese and at-risk normal weight postmenopausal women: The Women’s Health Initiative Observational Study. Obesity (Silver Spring) 2014; 22: 786–794.

11.

Scuteri

Laurent

Cucca

et al.

Metabolic syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol 2015; 22: 486–491.

12.

Schrover IM, van der Graaf Y, Spiering W, et al. The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. Eur J Prev Cardiol. 2018; 25: 1548–1557.

13.

Richard

Royer

Couture

et al.

Effect of the Mediterranean diet on plasma adipokine concentrations in men with metabolic syndrome. Metabolism 2013; 62: 1803–1810.

14.

Khoo

Dhamodaran

Chen

et al.

Exercise-induced weight loss is more effective than dieting for improving adipokine profile, insulin resistance, and inflammation in obese men. Int J Sport Nutr Exerc Metab 2015; 25: 566–575.

15.

Golbidi

Laher

. Exercise induced adipokine changes and the metabolic syndrome. J Diabetes Res 2014; 2014: 726861–726861.

16.

Garvey

Garber

Mechanick

et al.

on behalf of the Aace Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Consensus conference on obesity: Building an evidence base for comprehensive action. Endocr Pract 2014; 20: 956–976.

17.

Carlsson

Ärnlöv

Sundström

et al.

Physical activity, obesity and risk of cardiovascular disease in middle-aged men during a median of 30 years of follow-up. Eur J Prev Cardiol 2015; 23: 359–365.

18.

Flegal

Kit

Orpana

et al.

Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA 2013; 309: 71–82.

19.

Wildman

Muntner

Reynolds

et al.

The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008; 168: 1617–1624.

20.

Eckel

Meidtner

Kalle-Uhlmann

et al.

Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur J Prev Cardiol 2015; 23: 956–966.

21.

Brunzell

Hokanson

. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(Suppl. 3): C10–C13.

22.

Lee

Jung

et al.

Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 2010; 213: 592–597.

23.

Wang

Miao

. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin Exp Pharmacol Physiol 2011; 38: 888–896.

24.

Shah

Murthy

Abbasi

et al.

Visceral adiposity and the risk of metabolic syndrome across body mass index: The MESA Study. JACC Cardiovasc Imaging 2014; 7: 1221–1235.

25.

Amato

Pizzolanti

Torregrossa

et al.

Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 2014; 9: e91969–e91969.

26.

Nicklas

Penninx

Cesari

et al.

Association of visceral adipose tissue with incident myocardial infarction in older men and women: The Health, Aging and Body Composition Study. Am J Epidemiol 2004; 160: 741–749.

27.

Britton

Massaro

Murabito

et al.

Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013; 62: 921–925.

28.

Dahabreh

Kent

. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011; 305: 822–823.

29.

Smits

van Kuijk

Leffers

et al.

Index event bias-a numerical example. J Clin Epidemiol 2013; 66: 192–196.

30.

Mousa

Forsythe

Bozarth

et al.

Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993; 83: 367–373.

31.

Konig

Deibert

Winkler

et al.

Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease. Exerc Immunol Rev 2005; 11: 97–107.

32.

Shyu

Chua

Wang

et al.

Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. J Biomed Sci 2009; 16: 50–50.

33.

Jamaluddin

Weakley

Yao

et al.

Resistin: Functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012; 165: 622–632.

34.

Koh

Han

Quon

et al.

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005; 28: 1419–1424.

35.

Furuhashi

Ura

Higashiura

et al.

Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.

36.

Mantzoros

Williams

Manson

et al.

Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 2006; 84: 328–335.

37.

Esposito

Pontillo

Di Palo

et al.

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003; 289: 1799–1804.

38.

Bruno

Dwyer

et al.

Associations between alcohol consumption and cardio-metabolic risk factors in young adults. Eur J Prev Cardiol 2017; 24: 1967–1978.

39.

Beulens

de Zoete

Kok

et al.

Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: A diet intervention study. Eur J Clin Nutr 2008; 62: 1098–1105.

40.

Camhi

Bray

Bouchard

et al.

The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: Sex and race differences. Obesity (Silver Spring) 2011; 19: 402–408.

41.

Fantin

Comellato

Rossi

et al.

Relationship between neck circumference, insulin resistance and arterial stiffness in overweight and obese subjects. Eur J Prev Cardiol 2017; 24: 1532–1540.

42.

Farooq

Knez

et al.

Gender differences in fat distribution and inflammatory markers among Arabs. Mediators Inflamm 2013; 2013: 497324–497324.

43.

Luque-Ramirez

Martinez-Garcia

Montes-Nieto

et al.

Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum Reprod 2013; 28: 1908–1918.

44.

Alfadda

Sallam

Chishti

et al.

Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: Adipose depot specificity and gender dimorphism. Mol Cells 2012; 33: 591–596.

45.

Bluher

. Clinical relevance of adipokines. Diabetes Metab J 2012; 36: 317–327.

46.

Bluher

Rudich

Kloting

et al.

Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 2012; 35: 342–349.

47.

Steppan

Bailey

Bhat

et al.

The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–312.

48.

Hivert

Sullivan

Fox

et al.

Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008; 93: 3165–3172.

49.

Lindberg

Jensen

Bjerre

et al.

Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 2015; 22: 276–283.

50.

Wolk

Bertolet

Brooks

et al.

Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol 2016; 23: 50–58.

51.

Pokharel

Sun

Villareal

et al.

Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. Eur J Prev Cardiol 2017; 24: 628–638.